trending Market Intelligence /marketintelligence/en/news-insights/trending/jq-ttosu1bixbxx_q2hesq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Scythian Biosciences to acquire 49% stake in Jamaican cannabis company

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Scythian Biosciences to acquire 49% stake in Jamaican cannabis company

Scythian Biosciences Corp. plans to acquire a 49% stake in Marigold Projects Jamaica Ltd., a Jamaican company that has received conditional licenses to cultivate, process, sell and provide therapeutic or spa services utilizing cannabis products.

Under the proposed agreement, the Toronto-based company will issue 1.5 million common shares at C$23 apiece to the selling parties and will own a 49% interest in Marigold as well as a 95% royalty interest in the net revenues from products sold by Marigold.

Scythian's board engaged Clarus Securities Inc. to provide an opinion on the fairness of the acquisition to its shareholders and had received a verbal opinion that the consideration payable by the company is fair. However, the company will receive a final fairness opinion from Clarus Securities before signing a definitive agreement.

The acquisition is subject to regulatory approval by the TSX Venture Exchange and also remains subject to notification to the Jamaica Cannabis Licensing Authority.

Scythian is a research and development company focused on finding a solution for the prevention and treatment of mild and traumatic brain injury with its proprietary cannabinoid combination.